Maze Therapeutics, Inc. (MAZE) stock
MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$34.33−1.76 (-4.88%)
Close on Nov 13, 2026Market cap $1.91BP/E –Yield –
Maze Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Maze Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $136.88M, up 32.8% year over year. For fiscal 2025 it was $108.45M, up 29.9% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $108.45M | +29.9% |
| FY2024 | Dec 31, 2024 | $83.50M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $40.22M | +59.7% |
| Q2 FY2026 | Jun 30, 2026 | $34.94M | +24.3% |
| Q1 FY2026 | Mar 31, 2026 | $34.15M | +23.8% |
| Q4 FY2025 | Dec 31, 2025 | $27.57M | +24.1% |
| Q3 FY2025 | Sep 30, 2025 | $25.19M | +26.9% |
| Q2 FY2025 | Jun 30, 2025 | $28.11M | +43.8% |
| Q1 FY2025 | Mar 31, 2025 | $27.58M | +26.1% |
| Q4 FY2024 | Dec 31, 2024 | $22.22M | – |
| Q3 FY2024 | Sep 30, 2024 | $19.86M | – |
| Q2 FY2024 | Jun 30, 2024 | $19.55M | – |
| Q1 FY2024 | Mar 31, 2024 | $21.88M | – |
See a number that looks wrong?